BriaCell Therapeutics Shares Scheduled to Reverse Split on Wednesday, January 29th (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are set to reverse split before the market opens on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Stock Down 2.3 %

NASDAQ BCTX opened at $0.40 on Friday. The firm has a market capitalization of $17.54 million, a PE ratio of -0.45 and a beta of 1.55. The stock’s 50 day moving average is $0.64 and its 200 day moving average is $0.72. BriaCell Therapeutics has a twelve month low of $0.37 and a twelve month high of $4.37.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). On average, research analysts anticipate that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.